MyFinsight
Home
Blog
About
Contact
Download
Download image
Increase (decrease)in
notes payable
$58,836
Common stock issued for
cash
$50,000
Net cash provided by
(used in) financing...
$58,926
Canceled cashflow
$49,910
Net increase
(decrease) in cash
-$4,308
Canceled cashflow
$58,926
Net income (loss)
$991,927
Increase (decrease) in
accrued expenses
$147,302
Common stock issued for
expenses
$20,500
Increase (decrease) in
accounts payable
$9,126
Increase (decrease) in
interest expense...
$8,656
Borrowings from notes
payable to related...
-$49,910
Net cash provided by
(used in) operating...
-$63,234
Canceled cashflow
$1,177,511
Changes in derivative
liability
-$1,181,680
Increase ( decrease) in
unearned income
-$31,640
(increase) decrease in
accounts receivable
$27,424
Back
Back
Cash Flow
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)
source: myfinsight.com